Edition:
United Kingdom

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

83.16USD
18 Apr 2019
Change (% chg)

$0.81 (+0.98%)
Prev Close
$82.35
Open
$83.46
Day's High
$84.42
Day's Low
$81.23
Volume
695,298
Avg. Vol
378,659
52-wk High
$106.69
52-wk Low
$79.15

About

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products... (more)

Overall

Beta: 1.80
Market Cap(Mil.): $16,617.19
Shares Outstanding(Mil.): 175.27
Dividend: --
Yield (%): --

Financials

  BMRN.OQ Industry Sector
P/E (TTM): -- 29.30 32.55
EPS (TTM): -1.02 -- --
ROI: -5.48 14.23 13.83
ROE: -7.41 15.46 15.25

Catalyst Pharma sees net price of drug, once free, topping $300,000

NEW YORK Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.

11 Feb 2019

Catalyst Pharma sees net price of drug, once free, topping $300,000

NEW YORK, Feb 11 Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.

11 Feb 2019

BioMarin sets stage early for hemophilia cure off-Broadway

(This version of the November 21st story has been refiled to show in paragraph 23 that Sangamo Therapeutics has six people in clinical trials)

22 Nov 2018

Earnings vs. Estimates